Printer Friendly

THE IMMUNE RESPONSE CORP. DISCOVERS T CELLS INVOLVED IN RHEUMATOID ARTHRITIS

 THE IMMUNE RESPONSE CORP. DISCOVERS T CELLS
 INVOLVED IN RHEUMATOID ARTHRITIS
 SAN DIEGO, Dec. 2 /PRNewswire/ -- The Immune Response Corp. (NASDAQ/NMS: IMNR) announced today that it has discovered specific T cells in the joint tissue of rheumatoid arthritis patients that are implicated in the destruction of joints in these patients. Preventing the attack by these cells may halt the rheumatoid arthritis disease process and provide an effective treatment for the millions afflicted with this disease.
 These findings are published in today's issue of The Proceedings of the National Academy of Sciences.
 The company has discovered three closely related populations of T cells, VB17, VB14 and VB3, in the joints of rheumatoid arthritis patients. Immune Response believes that these T cells initiate the autoimmune attack against the joint tissue in rheumatoid arthritis patients. The T cells then recruit other immune cells to the joint, initiating a cascade of events that leads to inflammation, pain and joint destruction.
 The discovery of these specific T cells in the joints of rheumatoid arthritis patients represents a milestone in research on this disease. Traditional therapies for rheumatoid arthritis have addressed the disease symptoms, but have not halted the underlying attack against joints by the immune system. Immune suppressive therapies may inhibit this attack, but also weaken the immune system's ability to fight infections and disease. With the discovery of specific T cells causing rheumatoid arthritis, therapies can now be targeted at this small population of T cells without compromising the immune system.
 Immune Response is developing therapeutic vaccines based on receptors found on these specific T cells. The vaccines are intended to stimulate the immune system to inhibit or destroy these disease- causing cells and thereby prevent the destructive immune cascade at its initiation. Such an approach could provide a long-lasting, safe and effective treatment for rheumatoid arthritis.
 The company intends to file an Investigational New Drug application with the Food and Drug Administration in December of this year for Phase I/II human clinical trials in rheumatoid arthritis. Immune Response expects to begin clinical trials early in 1992 testing a therapeutic vaccine in patients suffering from rheumatoid arthritis.
 The Immune Response Corp. is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain autoimmune diseases, principally rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 -0- 12/2/91
 /CONTACT: Steven L. Basta of The Immune Response Corp., 619-431-7080/
 (IMNR) CO: The Immune Response Corp. ST: California IN: MTC SU:


DM-AL -- SD003 -- 8198 12/02/91 08:02 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 1991
Words:430
Previous Article:65 EXCEPTIONAL PROPERTIES EARN AAA'S FIVE DIAMONDS
Next Article:NATIONAL CITY CORPORATION NAMES DIGIROLAMO COORDINATOR OF MERCHANTS MERGER; TODD NAMED HEAD OF NATIONAL CITY'S COST REDESIGN PROGRAM
Topics:


Related Articles
IMMUNE RESPONSE FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR NEW RHEUMATOID ARTHRITIS TREATMENT
THE IMMUNE RESPONSE CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 1991 FINANCIAL RESULTS
THE IMMUNE RESPONSE CORPORATION BEGINS CLINICAL TRIAL OF NEW RHEUMATOID ARTHRITIS TREATMENT
THE IMMUNE RESPONSE CORPORATION BEGINS CLINICAL TRIAL OF NEW RHEUMATOID ARTHRITIS TREATMENT
THE IMMUNE RESPONSE CORP. BEGINS THIRD CLINICAL TRIAL OF RHEUMATOID ARTHRITIS TREATMENT
THE IMMUNE RESPONSE CORPORATION BEGINS RHEUMATOID ARTHRITIS PHASE II CLINICAL TRIAL
THE IMMUNE RESPONSE CORPORATION RECEIVES FDA CLEARANCE TO BEGIN PHASE II RHEUMATOID ARTHRITIS CLINICAL TRIAL
THE IMMUNE RESPONSE CORPORATION COMPLETES ENROLLMENT OF PHASE II CLINICAL TRIAL USING RHEUMATOID ARTHRITIS TREATMENT
The Immune Response Corporation Publishes Additional Findings On T Cells Involved in Psoriasis

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters